Exciting news for the medical community: The European Medicines Agency has officially approved the first-ever gene therapy for Hemophilia B, marking a transformative moment in rare disease management. This one-time treatment aims to significantly reduce or eliminate the need for lifelong factor IX infusions, offering patients greater freedom and improved quality of life. Healthcare professionals, this breakthrough is set to reshape care protocols and long-term health outcomes for those affected. Stay informed and explore how this innovation could impact your clinical practice!